186 related articles for article (PubMed ID: 28577954)
1. Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
Raskin J; Masrori P; Cant A; Snoeckx A; Hiddinga B; Kohl S; Janssens A; Cras P; Van Meerbeeck JP
Lung Cancer; 2017 Jul; 109():74-77. PubMed ID: 28577954
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
Uenami T; Hosono Y; Ishijima M; Kanazu M; Akazawa Y; Yano Y; Mori M; Yamaguchi T; Yokota S
Lung Cancer; 2017 Jul; 109():42-44. PubMed ID: 28577948
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab.
Jotatsu T; Oda K; Yamaguchi Y; Noguchi S; Kawanami T; Kido T; Satoh M; Yatera K
Immunotherapy; 2018 Feb; 10(2):85-91. PubMed ID: 29260625
[TBL] [Abstract][Full Text] [Related]
4. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
Narumi Y; Yoshida R; Minami Y; Yamamoto Y; Takeguchi S; Kano K; Takahashi K; Saito T; Sawada J; Terui H; Katayama T; Sasaki T; Ohsaki Y
BMC Cancer; 2018 Jan; 18(1):95. PubMed ID: 29361915
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.
Semper H; Muehlberg F; Schulz-Menger J; Allewelt M; Grohé C
Lung Cancer; 2016 Sep; 99():117-9. PubMed ID: 27565924
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient.
Abe J; Sato T; Tanaka R; Okazaki T; Takahashi S
Am J Case Rep; 2016 Nov; 17():880-882. PubMed ID: 27893699
[TBL] [Abstract][Full Text] [Related]
7. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
Leonardi GC; Oxnard GR; Haas A; Lang JP; Williams JS; Awad MM
J Immunother; 2017; 40(6):249-251. PubMed ID: 28557813
[TBL] [Abstract][Full Text] [Related]
8. Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review.
Hasegawa Y; Kawai S; Ota T; Tsukuda H; Fukuoka M
Immunotherapy; 2017 Aug; 9(9):701-707. PubMed ID: 28649876
[TBL] [Abstract][Full Text] [Related]
9. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.
Kashima J; Okuma Y; Shimizuguchi R; Chiba K
Cancer Immunol Immunother; 2018 Jan; 67(1):61-65. PubMed ID: 28913619
[TBL] [Abstract][Full Text] [Related]
10. IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma.
Kishi S; Minato M; Saijo A; Murakami N; Tamaki M; Matsuura M; Murakami T; Nagai K; Abe H; Nishioka Y; Doi T
Intern Med; 2018 May; 57(9):1259-1263. PubMed ID: 29279511
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status.
Chandrakanth MV; Noronha V; Joshi A; Patil V; Mahajan A; Prabhash K
Indian J Cancer; 2017; 54(1):55-56. PubMed ID: 29199664
[No Abstract] [Full Text] [Related]
12. Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report.
Daanen RA; Maas RJH; Koornstra RHT; Steenbergen EJ; van Herpen CML; Willemsen AECAB
J Immunother; 2017; 40(9):345-348. PubMed ID: 28961608
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.
Chen YH; Liu FC; Hsu CH; Chian CF
Medicine (Baltimore); 2017 Jul; 96(27):e7350. PubMed ID: 28682883
[TBL] [Abstract][Full Text] [Related]
14. Creatinine kinase elevation and peripheral neuropathy during nivolumab treatment of a patient with metastatic renal cell carcinoma.
Simsek M; Bilici M; Tekin SB
Indian J Cancer; 2018; 55(4):413-414. PubMed ID: 30829281
[TBL] [Abstract][Full Text] [Related]
15. Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer.
Iyoda T; Kurita N; Takada A; Watanabe H; Ando M
Am J Case Rep; 2018 Mar; 19():360-364. PubMed ID: 29581417
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer.
Badovinac S; Korsic M; Zarkovic K; Mursic D; Roglic M; Jakopovic M; Samarzija M
Immunotherapy; 2018 Mar; 10(6):427-431. PubMed ID: 29562858
[TBL] [Abstract][Full Text] [Related]
17. Understanding immunotherapy for the treatment of non-small cell lung cancer.
Thomas R
Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
[TBL] [Abstract][Full Text] [Related]
18. Case report of nivolumab-related pneumonitis.
Tada K; Kurihara Y; Myojo T; Kojima F; Ishikawa Y; Yoshiyasu N; Morimoto M; Ito R; Koyamada R; Yamashita T; Bando T; Mori S; Heike Y
Immunotherapy; 2017 Mar; 9(4):313-318. PubMed ID: 28303763
[TBL] [Abstract][Full Text] [Related]
19. Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer.
Dasanu CA; Lippman SM; Plaxe SC
J Oncol Pharm Pract; 2017 Dec; 23(8):638-640. PubMed ID: 27824586
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
